US · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 0.06 against a street estimate of 0.17 — a miss of 64.7%.
Analysts rate Dr. Reddy’s Laboratories Ltd ADR a hold (2 buy, 2 hold, 1 sell out of 5) with an average price target of $13.83.
| Fund | Stake |
|---|---|
| Robeco Institutional Asset Management BV | 2.16% |
| Morgan Stanley - Brokerage Accounts | 1.31% |
| BlackRock Inc | 1.27% |
| Royal Bank of Canada | 1.11% |
| Aikya Investment Management Ltd | 1.02% |
| Renaissance Technologies Corp | 0.88% |
| Dimensional Fund Advisors, Inc. | 0.64% |
| State Street Corp | 0.50% |
| Document | Date |
|---|---|
| Current report (6-K) · Q3 FY2027 OTHER NOTABLE POINTS • Dr. Reddy’s Laboratories Limited filed a Form 6-K with the U.S. Securities and Exchange Commission on October 14, 2026. • The | 2026-10-14 |
| Current report (6-K) · Q3 FY2027 OTHER NOTABLE POINTS • Dr. Reddy’s Laboratories Limited filed a Form 6-K with the U.S. Securities and Exchange Commission on October 8, 2026. • The | 2026-10-08 |
| Current report (6-K) · Q3 FY2027 HEADLINE NUMBERS • Dr. Reddy’s Laboratories will announce results for the quarter and six months ended September 30, 2026, on Friday, October 23, 202 | 2026-10-07 |
| Current report (6-K) · Q3 FY2027 HEADLINE NUMBERS • Dr. Reddy’s Laboratories’ US step-down wholly owned subsidiary, Dr. Reddy’s Laboratories, Inc. (DRL Inc.), received an IRS penalty | 2026-10-05 |
| Current report (6-K) · Q2 FY2027 OTHER NOTABLE POINTS • Dr. Reddy’s Laboratories will hold a Board meeting on Friday, October 23, 2026. • The Board will consider and approve the una | 2026-09-22 |
| Current report (6-K) · Q2 FY2027 OTHER NOTABLE POINTS • Dr. Reddy’s Laboratories disclosed that its management will participate in a Nomura investor conference on September 25, 2026. | 2026-09-21 |
| Current report (6-K) · Q2 FY2027 HEADLINE NUMBERS • Dr. Reddy’s entered an exclusive distribution and marketing agreement with Takeda for Qdenga® in India’s private market on Septemb | 2026-09-18 |
| Current report (6-K) · Q2 FY2027 REGULATORY UPDATE • The USFDA completed a records assessment at Dr. Reddy’s API manufacturing facility, Industrias Químicas Falcón de México, S.A. de | 2026-09-14 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | $0.08 / share ex-date Jul 24, 2026 · pay Aug 5, 2026 | 2026-07-24 |
| Dividend | $0.06 / share ex-date Jul 9, 2026 | 2026-07-09 |
| Split | 5 : 1 effective Nov 5, 2024 | 2024-11-05 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Dr. Reddy’s Laboratories Ltd ADR — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.